Jubilant Generics Limited

Saji Thomas

Indranil Nandi

Rajendra Shekhawat

Mohan Chikmagalur Sadashivappa

Rohit Chakravarthy

Bidyut Biswas

Chetan Balubhai Patel

M Umamaheshwar Prasad

Anilkumar Haribhat Lingabhat

The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities. More particularly, the present invention relates to process for the preparation of Losartan, Losartan potassium of Formula I or its other pharmaceutically acceptable salts thereof containing less than 10 ppm of each of the azido impurities, wherein the azido impurity is selected from the group comprising of 5-(4'-(azidomethyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole, 4&#x2032;-(azidomethyl)-[1,1&#x2032;-biphenyl]-2-carbonitrile, 4&#x2032;-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-carbonitrile, 5-(4&#x2032;-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole, 5-(azidomethyl)-2-butyl-4-chloro-1H-imidazole, 4&#x2032;-((4-(azidomethyl)-2-butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-carbonitrile, 5-(4&#x2032;-((4-(azidomethyl)-2-butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole and 1-((1-((2&#x2032;-(1H-tetrazol-5-yl)-[1,1&#x2032;-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl)-5-(4&#x2032;-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole. More particularly, the present invention relates to a simple, economical and industrially efficient process for the preparation of Losartan potassium of Formula I. 

Preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereof

Growing community of inventors

Noida, India

Saji Thomas